CorMedix Inc
$ 10.64
3.10%
04 Dec - close price
- Market Cap 838,316,000 USD
- Current Price $ 10.64
- High / Low $ 10.76 / 10.27
- Stock P/E 4.81
- Book Value 4.78
- EPS 2.21
- Next Earning Report 2026-03-31
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.16 %
- ROE 0.75 %
- 52 Week High 17.43
- 52 Week Low 5.60
About
CorMedix Inc. is a clinical-stage biopharmaceutical company based in Berkeley Heights, New Jersey, dedicated to developing and commercializing novel therapies for infectious and inflammatory diseases. The company targets critical unmet medical needs, particularly in infection prevention and management of inflammatory conditions, with a promising pipeline of products designed to enhance patient outcomes. CorMedix's commitment to innovation not only addresses significant healthcare challenges but also positions it favorably in a competitive market, making it an attractive opportunity for institutional investors seeking exposure to growth in the healthcare sector.
Analyst Target Price
$19.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-28 | 2025-08-07 | 2025-05-07 | 2025-03-10 | 2024-10-30 | 2024-08-14 | 2024-05-09 | 2024-03-12 | 2023-11-14 | 2023-08-08 | 2023-05-15 | 2023-03-30 |
| Reported EPS | 1.406 | 0.28 | 0.2993 | 0.22 | -0.05 | -0.25 | -0.25 | -0.26 | -0.17 | -0.25 | -0.24 | -0.2 |
| Estimated EPS | 0.2233 | 0.16 | 0.245 | 0.14 | -0.1 | -0.25 | -0.28 | -0.2 | -0.21 | -0.24 | -0.2 | -0.19 |
| Surprise | 1.1827 | 0.12 | 0.0543 | 0.08 | 0.05 | 0 | 0.03 | -0.06 | 0.04 | -0.01 | -0.04 | -0.01 |
| Surprise Percentage | 529.6462% | 75% | 22.1633% | 57.1429% | 50% | 0% | 10.7143% | -30% | 19.0476% | -4.1667% | -20% | -5.2632% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-31 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.7357 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRMD
2025-10-31 12:43:00
CorMedix Inc. will report its Q3 2025 financial results on November 12, 2025, before market open, followed by a conference call. The company is expanding its product portfolio through the acquisition of Melinta Therapeutics and has ongoing clinical studies for DefenCath. Topline results for the Phase III study of REZZAYO are anticipated by Q2 2026.
2025-08-29 00:00:00
CorMedix Inc. (CRMD) has announced the acquisition of Melinta Therapeutics, a strategic move to diversify its portfolio and expand its presence in the acute hospital care market. The combined company is projected to generate $305–$335 million in 2025 revenue and expects double-digit EPS growth in 2026. This acquisition aims to enhance CRMD's R&D and commercial capabilities and position it for broader recognition in the healthcare space.
2025-08-09 00:00:00
This article analyzes CorMedix Inc.'s (NASDAQ:CRMD) P/S ratio in comparison to the Pharmaceutical industry average in the United States. It highlights CorMedix's strong revenue growth and future revenue forecasts, which are higher than the industry, yet the company trades at a similar P/S ratio. The article suggests that investor skepticism or uncertainty about future forecasts might be keeping the stock price from fully reflecting its growth potential.
2025-07-02 20:31:00
CorMedix (CRMD) stock trended after announcing a new commercial supply contract with a mid-sized dialysis operator, significantly expanding the availability of its antimicrobial drug DefenCath. The agreement allows DefenCath to be supplied to dialysis clinics nationwide, covering approximately 60% of outpatient dialysis centers in the U.S., leading to a surge in message volume and a sustained 'bullish' retail sentiment for CRMD. The stock has risen over 150% year-to-date following its FDA approval last year.
2025-06-27 08:00:00
CorMedix (NASDAQ:CRMD) has announced the pricing of a public offering of 6,604,507 shares of common stock, expected to generate approximately $85 million in gross proceeds. The company plans to use these proceeds for general corporate purposes, including working capital, research and development expenses, and potential strategic transactions like acquisitions or joint ventures. RBC Capital Markets is acting as the sole bookrunner for the offering, which is expected to close around June 30, 2025.
2025-06-26 16:14:00
CorMedix Inc. announced its intention to offer and sell $85.0 million of its common stock in an underwritten public offering, with an option for underwriters to purchase an additional 15%. The proceeds will be used for general corporate purposes including research and development, working capital, and potential strategic transactions. RBC Capital Markets is acting as the sole bookrunner for the offering, which is subject to market conditions.
